STIMULATION OF OVULATION IN IMMATURE FEMALE RATS USING ORTHOSTERIC AND ALLOSTERIC LUTEINIZING HORMONE RECEPTOR AGONISTS

Abstract

Human chorionic gonadotropin (hCG) and luteinizing hormone (LH) are widely used for the treatment of reproductive disorders and for controlled ovulation induction, but their use is limited by side effects. Allosteric agonists of the LH/hCG receptor, including thieno[2,3-d]thienopyrimidine TP03 developed by us, can become an alternative. TP03 (50 mg/rat, i.p.) when administered to immature female rats treated 48 hours before with Follimag has been shown to increase progesterone levels (maximum 8 hours post-treatment) and induce ovulation, as indicated by the appearance at 24 hours corpus luteum (8.6 ± 0.5 per ovary). In terms of its activity, TP03 is comparable to hCG, although it acts more moderately. In the ovaries, unlike hCG, TP03 does not lead to an increase in the expression of vascular endothelial growth factor, which can cause ovarian hyperstimulation syndrome. Thus, TP03 is a promising drug as an ovulation inducer and ovarian steroidogenesis stimulator.